Filter Results:
(617)
Show Results For
- All HBS Web
(617)
- People (2)
- News (54)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
Show Results For
- All HBS Web
(617)
- People (2)
- News (54)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
- 01 May 2009
- Conference Presentation
The enabling and constraining effects of attention structures on entrepreneurial activity in the U.S. biodiesel industry
By: Shon R. Hiatt
- February 2010
- Background Note
Millipore Background Note
By: Elie Ofek and Natalie Kindred
This note provides background on Millipore Corporation, a global provider of products and services used primarily in the discovery, development and production of therapeutic drugs. With a track record of quickly adapting to the evolving needs of its customers,... View Details
Keywords: Organizational Change and Adaptation; Customer Focus and Relationships; Biotechnology Industry; Biotechnology Industry
Ofek, Elie, and Natalie Kindred. "Millipore Background Note." Harvard Business School Background Note 510-059, February 2010.
- July 2009
- Teaching Note
Khosla Ventures: Biofuels Strategy (TN)
Teaching Note for [809004]. View Details
- March 2009
- Teaching Note
Antegren: A Beacon of Hope (TN)
Teaching Note for [408025], [408026], [408027], and [408028]. View Details
- 2006
- Chapter
BioRisk: interleukin-2 from laboratory to market in the United States and Germany
By: Arthur A. Daemmrich
- June 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (C)
By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases. View Details
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (C)." Harvard Business School Case 603-045, June 2003. (Revised October 2004.)
- March 2002 (Revised May 2002)
- Case
Genzyme: Engineering the Market for Orphan Drugs
Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme's business model under new pressures. View Details
Keywords: Business Model; Information Technology; Market Entry and Exit; Biotechnology Industry; Biotechnology Industry
Chesbrough, Henry W., and Clarissa Ceruti. "Genzyme: Engineering the Market for Orphan Drugs." Harvard Business School Case 602-147, March 2002. (Revised May 2002.)
- September 2001
- Supplement
Millennium Pharmaceuticals, Inc. (B)
By: Stefan H. Thomke and Ashok Nimgade
Supplements the (A) case. View Details
Thomke, Stefan H., and Ashok Nimgade. "Millennium Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 602-063, September 2001.
- October 2000
- Teaching Note
Kendle International Inc. TN
By: Dwight B. Crane and Indra Reinbergs
Teaching Note for (9-200-033). View Details
- September 1997
- Case
Bayer AG (B)
By: John A. Quelch
Bayer's senior executives detail the communications challenge program that resulted from the company's reacquisition of its brand name and trademark cross, which gave Bayer one name worldwide for the first time since World War I. View Details
Keywords: Globalized Firms and Management; War; Acquisition; Trademarks; Brands and Branding; Communication Strategy; Biotechnology Industry; Biotechnology Industry; Germany
Quelch, John A., and Robin Root. "Bayer AG (B)." Harvard Business School Case 598-032, September 1997.
- 2000
- Chapter
In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals
By: Gary P. Pisano
Keywords: Competency and Skills; Research and Development; Biotechnology Industry; Biotechnology Industry
Pisano, Gary P. "In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals." Chap. 5 in The Nature and Dynamics of Organizational Capabilities, edited by Giovanni Dosi, Richard Nelson, and Sidney Winter, 129–154. New York: Oxford University Press, 2000.
- 31 Aug 2010
- First Look
First Look: August 31
a national sample of 6,000 life scientists whose careers span more than 20 years. We find sharp gender differences in participation in for-profit ventures, which we measure as the likelihood of joining the scientific advisory board (SAB) of a View Details
Keywords: Sean Silverthorne
- 01 Mar 2005
- News
A Primer on Patents
fifteen years ago, as a doctoral candidate in Harvard’s Economics Department, Lerner was collecting data on the role of VC funding in the biotechnology industry. Before long, he also became intrigued by the concept of intellectual... View Details
- 01 Mar 2003
- News
Naina Lal Kidwai
to the global automobile industry. Biotechnology and pharmaceutical firms are emerging as international players. There are also opportunities in infrastructure investment, such as telecom, ports, roads, and airports. Please comment on... View Details
- 06 Sep 2024
- Blog Post
Harvard Business School Announces 2024 Goldsmith Fellows
noted, “I’m excited to learn from other fellows and explore opportunities for collaboration across other systems, including policy, healthcare, and criminal justice.” Keemia Azvine. Keemia, who is pursuing a MS/MBA in Biotechnology Life... View Details
- 15 Dec 2020
- Blog Post
MBA Voices Blog: A Year in Review
decision maker. Read More 4 Things to Know About the MS/MBA Biotech “I was initially attracted to Harvard’s MS/MBA Biotechnology: Life Sciences program because of the emphasis on ethical decision making, and ultimately chose the program with the goal of becoming an... View Details
- 29 Jun 2022
- Blog Post
Harvard Business School Announces the 2022-2023 Blavatnik Fellows
led by Peter Barrett, PhD, faculty chair, and an advisory board of seasoned business and biotechnology leaders who serve as one-on-one mentors and provide strategic direction during the fellows' program year. “Since joining the Blavatnik... View Details
- September 2008 (Revised July 2012)
- Case
Khosla Ventures: Biofuels Strategy
By: Joseph B. Lassiter III, William A. Sahlman and Alison Berkley Wagonfeld
By 2008, a number of the firm's early cleantech investments were showing promise, and the companies were starting to need significantly more money to create the massive scale required in the energy sector. As Khosla thought about the hundreds of millions of dollars... View Details
Keywords: Entrepreneurial Marketing; Entrepreneurial Finance; New Product Development; Partnerships; Entrepreneurial Management; Venture Capital; Strategy; Partners and Partnerships; Renewable Energy; Entrepreneurship; Investment Funds; Environmental Sustainability; Product Development; Biotechnology Industry; Biotechnology Industry
Lassiter, Joseph B., III, William A. Sahlman, and Alison Berkley Wagonfeld. "Khosla Ventures: Biofuels Strategy." Harvard Business School Case 809-004, September 2008. (Revised July 2012.)
- September 2012 (Revised January 2014)
- Case
Aqua Bounty
By: Lucy White and Stephen Burn-Murdoch
Valuation of a pre-revenue biotech company at IPO using probability trees and real option techniques. Company is based in Massachusetts and lists in London on AIM. Products are genetically-modified fast-growing salmon for fish farmers and disease-prevention drugs and... View Details
Keywords: IPO; Valuation; Real Options; Decision Tree; Biotech; Genetically Modified; Salmon; Entrepreneurship; Finance; Biotechnology Industry; Biotechnology Industry; North and Central America; Europe; South America
White, Lucy, and Stephen Burn-Murdoch. "Aqua Bounty." Harvard Business School Case 213-047, September 2012. (Revised January 2014.)
- September 2000
- Case
Novartis Agricultural Discovery Institute (A)
Steve Briggs, a PhD biologist, is asked to propose a strategy to take global life-science giant Novartis into the rapidly expanding field of plant genomics. View Details
Keywords: Design; Plant-Based Agribusiness; Genetics; Infrastructure; Biotechnology Industry; Biotechnology Industry
West, Jonathan, and Christian G. Kasper. "Novartis Agricultural Discovery Institute (A)." Harvard Business School Case 601-010, September 2000.